TetterooEvan der GraafYBoschJL. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet. 1998; 351: 1153–1159.
2.
Collaborative overview of randomised trials of antiplatelet therapy—II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ. 1994; 308: 159–168.
3.
WhiteGHLiewSCWaughRC. Early outcome and intermediate follow-up of vascular stents in the femoral and popliteal arteries without long-term anticoagulation. J Vasc Surg.1995; 21: 270–279.
4.
WatsonHRBergqvistD. Antithrombotic agents after peripheral transluminal angioplasty: A review of the studies, methods and evidence for their use. Eur J Vasc Endovasc Surg.2000; 19: 445–450.
5.
BonviniRBaumgartnerIDoDD. Late acute thrombotic occlusion after endovascular brachytherapy and stenting of femoropopliteal arteries. J Am Coll Cardiol.2003; 41: 409–412.
6.
KuntzREBaimDS. Prevention of coronary restenosis: The evolving evidence base for radiation therapy. Circulation. 2000; 101: 2130–2133.
7.
GrenacherLSaamTGeierA. PTA versus Palmaz stent placement in femoropopliteal artery stenoses: Results of a multicenter prospective randomized study (REFSA). Rofo. 2004; 176: 1302–1310.
8.
SmithSCBlairSNBonowRO. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. J Am Coll Cardiol.2001; 38: 1581–1583.
9.
MacaTAhmadiRDerflerK. Elevated lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females?Atharosclerosis. 1996; 127: 27–34.
10.
SchillingerMHaumerMSchlerkaG. Restenosis after percutaneous transluminal angioplasty in the femoropopliteal segment: The role of inflammation. J Endovasc Ther.2001; 8: 477–483.
11.
HagenaarsTGussenhovenEJvan SambeekMR. Effect of simvastatin on restenosis after percutaneous transluminal angioplasty of femoropopliteal arterial obstruction. Am J Cardiol.2000; 86: 774–776, A6.
12.
van der LooBKovacevicTKriegerE. Blood fluidity and outcome after femoropopliteal percutaneous transluminal angioplasty (PTA): Role of plasma viscosity and low platelet count in predicting restenosis. Clin Hemorheol Microcirc. 2005; 32: 159–168.
13.
SchillingerMExnerMMlekuschW. Effect of smoking on restenosis during the 1st year after lower-limb endovascular interventions. Radiology. 2004; 231: 831–838.
14.
LaxdalEEideGEWirschingJ. Homocysteine levels, haemostatic risk factors and patency rates after endovascular treatment of the above-knee femoro-popliteal artery. Eur J Vasc Endovasc Surg.2004; 28: 410–417.
15.
KovacevicTvan der LooBAmann-VestiBR. Plasma homocysteine and restenosis after femoropopliteal angioplasty. J Endovasc Ther.2004; 11: 302–309.
16.
Dorffler-MellyJBullerHRKoopmanMM. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev.2003; (4): CD000536.
17.
Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery(The Dutch Bypass Oral Anticoagulants or Aspirin Study): A randomised trial. Lancet. 2000; 355: 346–351.
18.
SchneiderEBrunnerUBollingerA. Medikamentöse rezidivprophylaxe nach femoro-poplitealer arterienrekonstruktion. Angio. 1979; 2: 73–77.
19.
Dorffler-MellyJKoopmanMMAdamDJ. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev.2003; (3): CD000535.
20.
SaracTPHuberTSBackMR. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg.1998; 28: 446–457.
21.
JohnsonWCWillifordWO, members of the Department of Veterans Affairs Cooperative Study #362. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: A prospective randomized study. J Vasc Surg.2002; 35: 413–421.
22.
ClagettGPSobelMJacksonMR. Antithrombotic therapy in peripheral arterial occlusive disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126: 609S–626S.
23.
LamEYLandryGJEdwardsJM. Risk factors for autogenous infrainguinal bypass occlusion in patients with prosthetic inflow grafts. J Vasc Surg.2004; 39: 336–342.
24.
HenkePKBlackburnSProctorMC. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: Effect on graft patency, limb salvage, and mortality. J Vasc Surg.2004; 39: 357–365.
25.
AbbruzzeseTAHavensJBelkinM. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg.2004; 39: 1178–1185.
26.
GallinoADoDDAlerciM. Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: The PAB randomized multicenter trial. J Endovasc Ther.2004; 11: 595–604.
27.
NassCMAllenJKJermynRM. Secondary prevention of coronary artery disease in patients undergoing elective surgery for peripheral arterial disease. Vasc Med.2001; 6: 35–41.
28.
McDermottMMMehtaSAhnH. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med.1997; 12: 209–215.
29.
McDermottMMHahnEAGreenlandP. Atherosclerotic risk factor reduction in peripheral arterial diseases: Results of a national physician survey. J Gen Intern Med.2002; 17: 895–904.
30.
CambouJPFerrieresJGrenierO. Factors influencing secondary prevention of atherothrombotic disease in the private outpatient cardiology setting: Results of the Prisma survey [in French]. Ann Cardiol Angeiol (Paris). 2003; 52: 20–29.
31.
KrögerK. Postinterventionelle behandlung nach peripheren interventionen. Vasa. 2004; 36(S64): 73–79.
